Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with evidence of vascular disease are at increased risk for subsequent vascular events despite effective use of statins to lower the low-density lipoprotein (LDL) cholesterol level. Niacin lowers the LDL cholesterol level and raises the high-density lipoprotein (HDL) cholesterol level, but its clinical efficacy and safety are uncertain. METHODS: After a prerandomization run-in phase to standardize the background statin-based LDL cholesterol-lowering therapy and to establish participants' ability to take extended-release niacin without clinically significant adverse effects, we randomly assigned 25,673 adults with vascular disease to receive 2 g of extended-release niacin and 40 mg of laropiprant or a matching placebo daily. The primary outcome was the first major vascular event (nonfatal myocardial infarction, death from coronary causes, stroke, or arterial revascularization). RESULTS: During a median follow-up period of 3.9 years, participants who were assigned to extended-release niacin-laropiprant had an LDL cholesterol level that was an average of 10 mg per deciliter (0.25 mmol per liter as measured in the central laboratory) lower and an HDL cholesterol level that was an average of 6 mg per deciliter (0.16 mmol per liter) higher than the levels in those assigned to placebo. Assignment to niacin-laropiprant, as compared with assignment to placebo, had no significant effect on the incidence of major vascular events (13.2% and 13.7% of participants with an event, respectively; rate ratio, 0.96; 95% confidence interval [CI], 0.90 to 1.03; P=0.29). Niacin-laropiprant was associated with an increased incidence of disturbances in diabetes control that were considered to be serious (absolute excess as compared with placebo, 3.7 percentage points; P<0.001) and with an increased incidence of diabetes diagnoses (absolute excess, 1.3 percentage points; P<0.001), as well as increases in serious adverse events associated with the gastrointestinal system (absolute excess, 1.0 percentage point; P<0.001), musculoskeletal system (absolute excess, 0.7 percentage points; P<0.001), skin (absolute excess, 0.3 percentage points; P=0.003), and unexpectedly, infection (absolute excess, 1.4 percentage points; P<0.001) and bleeding (absolute excess, 0.7 percentage points; P<0.001). CONCLUSIONS: Among participants with atherosclerotic vascular disease, the addition of extended-release niacin-laropiprant to statin-based LDL cholesterol-lowering therapy did not significantly reduce the risk of major vascular events but did increase the risk of serious adverse events. (Funded by Merck and others; HPS2-THRIVE ClinicalTrials.gov number, NCT00461630.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the EU, treatment with niacin was stopped after the AIM-HIGH and HPS2-THRIVE trials showed no improvement in MACE and an increased occurrence of undesirable side effects [123, 124].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [124]
In the citing paper
“Nonetheless, these studies also did not prospectively enroll patients with elevated TG levels despite statin therapy,6, 12, 13, 14, 15”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [14]
In the citing paper
“Prior CV outcome studies that administered therapies with TG‐lowering effects (niacin or fenofibrate) on top of statin therapy did not reach their primary endpoints.”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [14]
In the citing paper
“and an increased incidence of new-onset diabetes (absolute excess, 1.3 percentage points; P < 0.001) and disturbances in diabetes management among those with diabetes in the HPS2-THRIVE trial in those on combination therapy (161).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [161]
In the citing paper
“Large clinical trials, including the Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) and Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trials, failed to demonstrate a benefit of adding niacin to individuals on appropriate statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [161]
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Prostaglandins and Inflammation
Ricciotti, E., & FitzGerald, G. A. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.207449 · Cited by 3,803
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Clofibrate and Niacin in Coronary Heart Disease
(1975) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1975.03240160024021 · Cited by 1,747
Cited by
Items 801–900 of 1,676
Andrews, J., Puri, R., Kataoka, Y., Nicholls, S. J., & Psaltis, P. J. (2016) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2015.10.02 · Cited by 18
Robinson, J. G. (2016) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2016.07.011 · Cited by 15
Genetic Variants Associated With Plasma Lipids Are Associated With the Lipid Response to Niacin
Tuteja, S., Qu, L., Vujković, M., Dunbar, R. L., Chen, J., DerOhannessian, S. L., & Rader, D. J. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.008461 · Cited by 15
“7,8 The mechanisms underlying the lipid-lowering effects of niacin are still unresolved.”
Managing dyslipidemia for CVD prevention: A review of recent clinical practice guidelines
Ciffone, N. A., & COPPLE, T. M. (2018) · The Nurse Practitioner · doi:10.1097/01.npr.0000550246.96902.de · Cited by 20
Ruuth, M. K., Soronen, J., Kaiharju, E., Merikanto, K., Perttilä, J., Metso, J., Lee‐Rueckert, M., Taskinen, M., Kovanen, P. T., Öörni, K., et al. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0930-2 · Cited by 14
Evidence-Based Cardiovascular Risk Management in Diabetes
Mooradian, A. D. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00336-6 · Cited by 16
Pharmacokinetics of current and emerging treatments for hypercholesterolemia
Tomlinson, B., Chan, P., Zhang, Y., Liu, Z., & Lam, C. W. K. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1749261 · Cited by 17
“showed some adverse effects and no overall benefit [20,21] and prescription formulations of niacin are no longer available in most countries.”
BackgroundTherapeutic Lowering of Lipoprotein(a)
Boffa, M. B., & Koschinsky, M. L. (2018) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.118.002052 · Cited by 15
Human genetic insights into lipoproteins and risk of cardiometabolic disease
Stitziel, N. O. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000389 · Cited by 14
Pan, K., Jiang, H., Dowling, R., Zhong, L., Ke, L., Xu, M., Wang, C., Tian, Q., He, Y., Lu, K., et al. (2022) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-021-01347-6 · Cited by 15
Tada, H., Okada, H., Nohara, A., et al. (2022) · Circulation Journal · doi:10.1253/circj.cj-22-0560 · Cited by 14
LP(a): The new marker of high cardiovascular risk
Averna, M. R., & Cefalu, A. B. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.103845 · Cited by 17
Fibrates and niacin: is there a place for them in clinical practice?
Wierzbicki, A. S., & Viljoen, A. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.972365 · Cited by 15
“Following the results of the AIM-HIGH and HPS2/ THRIVE studies the risk-benefit ratio of niacin is increasingly being questioned [38].”
BackgroundMethodInfluentialBoffa, M. B. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0622-1 · Cited by 15
Statin-Associated Muscle Adverse Events: Update for clinicians
Al‐Mohaissen, M. A., Ignaszewski, M. J., Frohlich, J. J., & Ignaszewski, A. (2016) · Sultan Qaboos University medical journal · doi:10.18295/squmj.2016.16.04.002 · Cited by 18
Tuteja, S., Wang, L., Dunbar, R. L., Chen, J., DerOhannessian, S. L., Marcovina, S. M., Elam, M. B., Lader, E. W., & Rader, D. J. (2017) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000289 · Cited by 15
Dyslipidaemia in the elderly: to treat or not to treat?
Katsiki, N., Kolovou, G. D., Pérez‐Martínez, P., & Mikhailidis, D. P. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1425138 · Cited by 14
Diagnosis and Management of Dyslipidemia
Myerson, M. L. (2019) · Springer eBooks · doi:10.1007/978-3-030-10451-1_3 · Cited by 14
Matsushita, K., Hibi, K., Komura, N., Kimura, Y., Matsuzawa, Y., Konishi, M., Maejima, N., Iwahashi, N., Kosuge, M., Ebina, T., et al. (2020) · Journal of Cardiology · doi:10.1016/j.jjcc.2020.01.005 · Cited by 14
Cholesteryl ester transfer protein inhibitors in precision medicine
Su, X., Li, G., Deng, Y., & Chang, D. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.09.012 · Cited by 14
Zhou, R., Stouffer, G. A., & Smith, S. C. (2021) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484211023632 · Cited by 15
Norbitt, C. F., Kimita, W., Bharmal, S. H., Ko, J., & Petrov, M. S. (2022) · Nutrients · doi:10.3390/nu14071480 · Cited by 17
“However, pharmacological doses of vitamin B3 may have detrimental effects on glycaemic control in individuals with [83] and without diabetes [82,83].”
BackgroundResultGynostemma pentaphyllum for dyslipidemia: A systematic review of randomized controlled trials
Dai, N., Zhao, F., Fang, M., Pu, F., Kong, L., & Liu, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.917521 · Cited by 20
“hemoglobin and affect the control of blood glucose in diabetic patients (Aim-High et al., 2011; Group et al., 2014).”
BackgroundIcosapent Ethyl: A Review of Its Use in Severe Hypertriglyceridemia
Kim, E. S., & McCormack, P. L. (2014) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-014-0099-7 · Cited by 16
Zhong, Y., Lin, S. L., & Schooling, C. M. (2016) · Preventive Medicine · doi:10.1016/j.ypmed.2016.09.003 · Cited by 18
HDL infusion for the management of atherosclerosis: current developments and new directions
Zheng, K. H., & Stroes, E. S. G. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000349 · Cited by 16
Therapeutic Targeting of Cellular Stress to Prevent Cardiovascular Disease: A Review of the Evidence
Mooradian, A. D. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0199-7 · Cited by 15
Weiss, M. C., Berger, J. S., Gianos, E., Fisher, E. A. A., Schwartzbard, A. Z., Underberg, J. A., & WEINTRAUB, H. S. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.07.005 · Cited by 14
PCSK9 inhibitors: a non-statin cholesterol-lowering treatment option
Pokrywka, G. S. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2018.1436843 · Cited by 13
Alkhalil, M. (2018) · Current Drug Metabolism · doi:10.2174/1389200219666180816141827 · Cited by 14
Kobayashi, D., Noto, H., Shimbo, T., Ino, T., Osugi, Y., Takahashi, O., & Asai, K. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.06.918 · Cited by 14
TRPV1 Channels Are Involved in Niacin-induced Cutaneous Vasodilation in Mice
Clifton, H. L., İnceoğlu, B., Ma, L., Zheng, J., & Schaefer, S. (2014) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000181 · Cited by 15
Javaheri, A., Molina, M. R., Zamani, P. L., Rodrigues, A., Novak, E. L., Chambers, S. V., Stutman, P., Maslanek, W., Williams, M., Lilly, S. M., et al. (2016) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2016.06.022 · Cited by 15
Simone, R. D. (1994) · Springer eBooks · doi:10.1007/978-3-642-78956-4_5 · Cited by 14
Glycemic Targets and Prevention of Complications
Tsushima, Y., & Galloway, N. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae776 · Cited by 21
Schuitema, P. C. E., Visseren, F. L. J., Nordestgaard, B. G., Teraa, M., van der Meer, M. G., Ruigrok, Y. M., Onland‐Moret, N. C., & Koopal, C. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120411 · Cited by 21
Is HPS2-THRIVE the death knell for niacin?
Toth, P. P., Murthy, A., Sidhu, M. S., & Boden, W. E. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.01.008 · Cited by 13
Yang, S.-Q., Liu, H.-X., Yu, X.-Q., Tong, L., Chen, X., Qi, L.-Y., Cui, C.-Y., Cheng, L.-C., & Cai, L. (2022) · Coronary Artery Disease · doi:10.1097/mca.0000000000001134 · Cited by 16
Sowa, P. W., Winzer, E. B., Hommel, J., Männel, A., Craenenbroeck, E. M. V., Wisløff, U., Pieske, B. M., Halle, M., Linke, A. H.-P., & Adams, V. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14032 · Cited by 14
Quesada, J. A., Bertomeu‐González, V., Orozco‐Beltrán, D., Cordero, A., Gil-Guillén, V. F., López‐Pineda, A., Nouni-García, R., & Carratalá‐Munuera, C. (2022) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2022.11.001 · Cited by 17
Farina, J., Pereyra, M., Mahmoud, A., Chao, C., Barry, T., Demeter, S. H., Ayoub, C., & Arsanjani, R. (2023) · Pharmaceuticals · doi:10.3390/ph16070919 · Cited by 14
Yamashita, S., Hirano, T., Shimano, H., Tsukamoto, K., Yoshida, M., & Yoshida, H. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14227 · Cited by 14
“17,18 Consequently, they have been withdrawn from the market in Europe, and the United States Food and Drug Administration also concluded that there was insufficient evidence for reducing cardiovascular events.”
Current Drug Treatment of Hyperlipidemia in Older Adults
Dixon, D. L., Donohoe, K. L., Ogbonna, K. C., & Barden, S. M. (2015) · Drugs & Aging · doi:10.1007/s40266-015-0240-6 · Cited by 14
Zheng, D., Nel, A., Wang, H., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-01710-7 · Cited by 13
Lipoprotein(a)-apheresis in the light of new drug developments
Vogt, A. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2017.05.025 · Cited by 14
“[25] Group, HTC, Landray, MJ, Haynes, R, et al.”
Safety assessment of niacin in the US Food and Drug Administration's mini‐sentinel system
Gagne, J. J., Houstoun, M., Reichman, M. E., Hampp, C., Marshall, J. H., & Toh, S. (2017) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4343 · Cited by 13
“50).(5) In January 2013, Merck announced a worldwide withdrawal of the combination niacin and laropiprant product following recommendations from the European Medicines Agency's Pharmacovigilance Risk Assessment Committee.”
BackgroundRiesgo cardiovascular residual de origen lipídico. Componentes y aspectos fisiopatológicos
Hernández‐Mijares, A., Ascaso, J. F., Blasco, M., Brea, Á., Rodríguez, Á. D., Mantilla, T., Pedro‐Botet, J., Pintó, X., & Millán, J. (2018) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2018.06.007 · Cited by 17
Case, B. C., Bress, A. P., Kolm, P., Philip, S., Herrick, J. S., Granowitz, C. B., Toth, P. P., Fan, W., Wong, N. D., HULL, M. L., et al. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.07.004 · Cited by 14
Kapoor, K., Alfaddagh, A., Stone, N. J., & Blumenthal, R. S. (2021) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.06.004 · Cited by 14
Macrophage SR-B1 in atherosclerotic cardiovascular disease
Huby, T., & Goff, W. L. (2022) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000822 · Cited by 13
“However, intervention studies aimed at increasingHDL-Clevels [5,6], infusionofrecombinant HDL[7,8]andMendelianrandomizationstudies[9]do not support a causal role of HDL in CVD.”
BackgroundColesevelam – a bile acid sequestrant for treating hypercholesterolemia and improving hyperglycemia
Esan, O., Viljoen, A., & Wierzbicki, A. S. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2112945 · Cited by 15
“Statins increase HbA1c by 2.4 mmol/mol (0.3% HbA1c) and the risk of developing T2DM by 11% in susceptible individuals with the metabolic syndrome [80] possibly in a dose-proportional manner but the size of the effect is small compared to their benefits in reducing CVD events [81,82].”
MethodInfluentialMszar, R., Bart, S., Sakers, A. P., Soffer, D. E., & Karalis, D. G. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041382 · Cited by 17
“Niacin • AIM HIGH (2011) [64] • HPS2-Thrive (2014) [65]”
Evolocumab in the treatment of dyslipidemia: pre-clinical and clinical pharmacology
Page, M. M., & Watts, G. F. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1073712 · Cited by 14
“Nicotinic acid lowers plasma levels of Lp(a) by about 25%, but is not well-tolerated nor commonly used [22].”
BackgroundLowering triglycerides to modify cardiovascular risk: will icosapent deliver?
Nicholls, S. J., & Scherer, D. J. (2015) · Vascular Health and Risk Management · doi:10.2147/vhrm.s40134 · Cited by 17
Khaliq, A., Johnson, B. D., Anderson, R. D., Bavry, A. A., Cooper‐DeHoff, R. M., Handberg, E. M., Merz, C. N. B., Nicholls, S. J., Nissen, S. E., & Pepine, C. J. (2015) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000049 · Cited by 14
Serum inhibitory factor 1, high-density lipoprotein and cardiovascular diseases
Martinez, L. O., Genoux, A., Ferrières, J., Duparc, T., & Perret, B. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000434 · Cited by 13
Yamamoto, R., Sacks, F. M., Hu, F. B., ROSNER, B. A., Furtado, J. D., Aroner, S. A., Ferrannini, E., Baldi, S., Kozàkovà, M., Balkau, B., et al. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.12.029 · Cited by 13
Allard‐Ratick, M., Sandesara, P. B., Quyyumi, A. A., & Sperling, L. S. (2019) · US Cardiology Review · doi:10.15420/usc.2019.3.2 · Cited by 13
Fras, Z. (2019) · The Anatolian Journal of Cardiology · doi:10.14744/anatoljcardiol.2019.56068 · Cited by 13
“Currently, the use of this drug in clinical practice is significantly limited since unfortunately, later trials showed that niacin co-administered with statins in patients with CVD does not improve cardiovascular outcomes and is also associated with an increased risk of adverse events, so the expected potential net be…”
BackgroundHui, N., Phan, K. H., Kerferd, J., et al. (2019) · Journal of Spine Surgery · doi:10.21037/jss.2019.09.27 · Cited by 13
Precision Medicine and Cardiovascular Health: Insights from Mendelian Randomization Analyses
Spiller, W., Jung, K. J., Lee, J., & Jee, S. H. (2019) · Korean Circulation Journal · doi:10.4070/kcj.2019.0293 · Cited by 13
Management of Hyperlipidemia After Stroke
Brooks, D. C., & Schindler, J. (2019) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-019-0774-8 · Cited by 13
Role of niacin in current clinical practice
Sharma, A., & Madan, N. (2019) · Minerva Medica · doi:10.23736/s0026-4806.18.05826-3 · Cited by 15
Obesity and Ischemic Heart Disease: Defining the Link
McPherson, R. (2015) · Circulation Research · doi:10.1161/circresaha.115.305826 · Cited by 14
Agricultural Development in Asia
(1971) · International Affairs · doi:10.1093/ia/47.4.865a · Cited by 13
Triglycerides, Glucose Metabolism, and Type 2 Diabetes
Wang, Y. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26209910 · Cited by 26
Dicarbonyl-modified lipoproteins contribute to proteinuric kidney injury
Zhong, J., Yang, H., Shelton, E. L., Matsusaka, T., Clark, A. J., Yermalitsky, V. N., Mashhadi, Z., Zhang, L., Linton, M. F., Fogo, A. B., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.161878 · Cited by 13
Antihyperlipidemic Treatment Options in Statin Resistance and Intolerance
Danilov, A., Frishman, W. H., & Aronow, W. S. (2022) · Cardiology in Review · doi:10.1097/crd.0000000000000498 · Cited by 12
Loh, W. J., & Watts, G. F. (2022) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000789 · Cited by 12
“Although niacin also lowers Lp(a) by about 20–25%, niacin was not found to improve cardiovascular outcomes in two large clinical trials, perhaps due to the lack of patients with elevated Lp(a) levels [69,70].”
BackgroundChen, L., Zhao, Y., Wang, Z., Wang, Y., Bo, X., Jiang, X., Hao, C., Ju, C., Qu, Y., & Dong, H. (2023) · BMC Cardiovascular Disorders · doi:10.1186/s12872-023-03383-9 · Cited by 13
Razavi, A. C., Bhatia, H. S., Blumenthal, R. S., Shapiro, M. D., & Mehta, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16469 · Cited by 18
“71,72 Due to the lack of benefit and adverse effects, niacin is not currently recommended for ASCVD prevention.”
Cardiovascular prevention—end of the road for niacin?
Tuteja, S., & Rader, D. J. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.159 · Cited by 12
McKenney, J. M., Bays, H. E., Gleim, G. W., Mitchel, Y., Kuznetsova, O., Sapre, A., Sirah, W., & Maccubbin, D. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.02.006 · Cited by 13
Newsom, L. C. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014564181 · Cited by 13
Implications for REDUCE IT in clinical practice
Bittner, V. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.11.003 · Cited by 13
Novel aspects on the role of white adipose tissue in type 2 diabetes
Mejhert, N., & Rydén, M. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.09.008 · Cited by 14
Tackling cardiometabolic risk in the Asia Pacific region
Li, J., Yeo, K. K., Tan, K., Ako, J., Krittayaphong, R., Tan, R., Aylward, P. E., Lam, C. S. P., Baek, S. H., Dalal, J. J., et al. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100096 · Cited by 14
Ketteler, M., Więcek, A., Rosenkranz, A. R., Ose, C., Rekowski, J., Lorenz, H., Hellmann, B., Karus, M., Ruhmann, M., & Ammer, R. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac206 · Cited by 12
“In the HPS2-THRIVE trial, niacin/laropiprant was associated with a significantly increased incidence of serious infections in patients with vascular disease [44].”
BackgroundThe pleiotropic effects of high-density lipoproteins and apolipoprotein A-I
Thomas, S. R., Zhang, Y., & Rye, K. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101689 · Cited by 19
Lipid Management in Human Immunodeficiency Virus
Myerson, M. L. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2015.09.010 · Cited by 12
Dandapat, S., & Robinson, J. G. (2016) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-016-0621-1 · Cited by 12
Managing the lipid profile of coronary heart disease patients
Drakopoulou, M. I., Toutouzas, K. P., Stathogiannis, K. E., Synetos, A. G., Trantalis, G., & Tousoulis, D. M. (2016) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2016.1221341 · Cited by 16
CANHEART: Is HDL cholesterol a cardiovascular specific risk factor?
Hassan, M. S., & Philip, P. (2017) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2016.34 · Cited by 13
ADVERSE EFFECTS AND SIDE EFFECTS ON VITAMIN THERAPY: A REVIEW
Korah, M. C., Pv, J. R., P, R. R., Behanan, A., Paul, E. P., & Sivakumar, T. (2017) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2017.v10i5.17014 · Cited by 17
“diabetes are also reported for niacin [58-62].”
BackgroundIncreasing HDL-C levels with medication: current perspectives
Smit, R. A. J., Jukema, J. W., & Trompet, S. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000426 · Cited by 14
Efficacy of Laropiprant in Minimizing Brain Injury Following Experimental Intracerebral Hemorrhage
Ahmad, A. S., Mendes, M. S., Hernandez, D., & Doré, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-09994-5 · Cited by 11
Treating Dyslipidemia in Type 2 Diabetes
Nelson, A. J., & Nicholls, S. J. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.005 · Cited by 14
Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events
Lee, S., & Cannon, C. P. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-0997-4 · Cited by 12
Patoulias, D., Stavropoulos, K., Imprialos, K. P., Athyros, V. G., Doumas, M. N., & Karagiannis, A. I. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117666190426162746 · Cited by 13
Boffa, M. B., & Koschinsky, M. L. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000641 · Cited by 15
Icosapent Ethyl: Niche Drug or for the Masses?
Bazarbashi, N., & Miller, M. J. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01356-4 · Cited by 12
Yubero‐Serrano, E. M., Alcala-Diaz, J. F., Gutierrez-Mariscal, F. M., Larriva, A. P. A.-D., Peña‐Orihuela, P. J., Blanco-Rojo, R., Martínez-Botas, J., Torres-Peña, J. D., Pérez‐Martínez, P., Ordovás, J. M., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01260-3 · Cited by 13
Greiner, R., Nyirenda, M., Rodgers, L. R., Asiki, G., Banda, L., Shields, B. M., Hattersley, A. T., Crampin, A. C., Newton, R., & Jones, A. G. (2020) · BMJ Global Health · doi:10.1136/bmjgh-2021-005222 · Cited by 12
Genetic insights into statin-associated diabetes risk
Swerdlow, D. I., & Preiss, D. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000272 · Cited by 15
“One known side-effect of niacin, an agent which increases HDL-cholesterol and lowers LDL-cholesterol and triglycerides, is that it moderately increases blood glucose and the risk of developing diabetes [17,18].”
BackgroundUribe, K. B., Benito‐Vicente, A., Martín, C., Blanco‐Vaca, F., & Rotllán, N. (2021) · Biomaterials Science · doi:10.1039/d0bm01838d · Cited by 14
Moore, M. K., Jones, G. T., McCormick, S., Williams, M. J. A., & Coffey, S. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae100 · Cited by 11
The Role of Lipoprotein(a) in Peripheral Artery Disease
Pavlatos, N., & Kalra, D. K. (2024) · Biomedicines · doi:10.3390/biomedicines12061229 · Cited by 17
“Lp(a) levels were measured in 1999 randomly selected patients one year into the study; however, they found that patients taking niacin and laropiprant had levels 17.8% lower than statin alone (50.7 vs. 60.3 nmol/L) [89].”
MethodInfluentialZhou, J., & Wang, X. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107387 · Cited by 15
Remnant Cholesterol: Should it be a Target for Prevention of ASCVD?
Doi, T., Langsted, A., & Nordestgaard, B. G. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01288-w · Cited by 13
Emerging innovative therapeutic approaches targeting PCSK9 to lower lipids
Shantha, G., & Robinson, J. G. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.281 · Cited by 12
Metadata
- Authors
- The HPS2-THRIVE Collaborative Group
- Corresponding author
- The HPS2-THRIVE Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-07-17
- Volume
- 371
- Issue
- 3
- Pages
- 203-212
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1856460279
- Cited by
- 1,668
- References
- 33
- Citations by year
- 2026: 72 · 2025: 73 · 2024: 107 · 2023: 113 · 2022: 115 · 2021: 119 · 2020: 132 · 2019: 144 · 2018: 149 · 2017: 159 · 2016: 203 · 2015: 204 · 2014: 71
- FWCI
- 210.23
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion, other-oa)
- Funders
- Harbin Medical University
- Second Affiliated Hospital of Harbin Medical University
- Cancer Research UK
- National Institute for Health and Care Research (CDF-2013-06-012)
- British Heart Foundation (RE/08/004)
- Tongji University
- Zhengzhou University
- Qingdao University
- First Affiliated Hospital of Zhengzhou University
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- extended-release niacin, laropiprant, LDL cholesterol lowering, HDL cholesterol, major vascular events, secondary prevention, vascular disease, statin therapy, diabetes management, adverse events, cardiovascular risk reduction, lipid-lowering therapy, coronary artery disease, stroke, myocardial infarction, arterial revascularization, infection risk
- MeSH terms
- Aged, Hypolipidemic Agents, Delayed-Action Preparations, Diabetes Mellitus, Double-Blind Method, Drug Combinations, Female, Follow-Up Studies, Hemorrhage, Humans, Hypercholesterolemia, Indoles, Infections, Cholesterol, LDL, Male, Middle Aged, Musculoskeletal Diseases, Niacin, Risk Factors, Treatment Failure, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.